Aligos Therapeutics to Announce 3rd Quarter Results on November 2, 2023
October 26, 2023 16:05 ET
|
Aligos Therapeutics
SOUTH SAN FRANCISCO, Calif., Oct. 26, 2023 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on developing novel therapeutics to...
Aligos Therapeutics To Present Late Breaking Poster on ALG-000184, its CAM-E Drug Candidate, at The Liver Meeting® 2023
October 25, 2023 08:00 ET
|
Aligos Therapeutics
SOUTH SAN FRANCISCO, Calif., Oct. 25, 2023 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on developing novel therapeutics to...
Aligos Therapeutics Announces $92 Million Private Placement Financing
October 23, 2023 08:00 ET
|
Aligos Therapeutics
Proceeds expected to fund the following:- NASH (ALG-055009): top line data from Phase 2a study (Q4 2024)- Hepatitis B/CAM-E (ALG-000184): Phase 2 enabling activities (H2 2024)- Funding expected to...
Aligos Therapeutics Announces Award of an $8.5 Million NIAID Contract to Advance Development of Best-In-Class Pan-Coronavirus Protease Inhibitor, ALG-097558
October 03, 2023 07:30 ET
|
Aligos Therapeutics
- NIAID contract will support conducting nonclinical and clinical studies to advance ALG-097558 into future Phase 2/3 studies - This is the second NIH-funding received to advance the development of...
Aligos Therapeutics Announces IND Clearance for NASH lead, ALG-055009
September 21, 2023 07:30 ET
|
Aligos Therapeutics
SOUTH SAN FRANCISCO, Calif., Sept. 21, 2023 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”), a clinical stage biopharmaceutical company focused on developing novel...
Aligos Therapeutics Reports Recent Business Progress and Second Quarter 2023 Financial Results
August 03, 2023 16:05 ET
|
Aligos Therapeutics
SOUTH SAN FRANCISCO, Calif., Aug. 03, 2023 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on developing novel therapeutics to...
Aligos Therapeutics to Announce Second Quarter Results on August 03, 2023
July 27, 2023 16:05 ET
|
Aligos Therapeutics
SOUTH SAN FRANCISCO, Calif., July 27, 2023 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”, the “Company”), a clinical stage biopharmaceutical company focused on developing...
Aligos Therapeutics Announces the Selection of Stephen Harrison, MD as Principal Investigator of Ph2a Study and Key Study Design Elements/Milestones for NASH Drug Candidate, ALG-055009
July 19, 2023 07:30 ET
|
Aligos Therapeutics
- Phase 1 study conduct complete with preliminary data indicating THR-beta agonist ALG-055009 was well-tolerated with a favorable PK profile and dose responsive changes in relevant biomarkers ...
Aligos Therapeutics Presents Data from its Liver Disease Programs at the European Association for the Study of the Liver (EASL) Congress 2023
June 21, 2023 16:30 ET
|
Aligos Therapeutics
-Presentations include a late breaking poster from an ongoing Phase 1b study of ALG-000184 demonstrating multi-log reductions in HBsAg, DNA, and RNA levels in subjects dosed for up to 36 weeks- -Data...
Aligos Therapeutics to Present Data on its Liver Disease Programs at the European Association for the Study of the Liver (EASL) Congress 2023
June 07, 2023 07:30 ET
|
Aligos Therapeutics
SOUTH SAN FRANCISCO, Calif., June 07, 2023 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on developing novel therapeutics to...